Tag
The LAST-long trial investigated a community-based, individualized stroke intervention and found that age—but not frailty—significantly modifies its effectiveness, with older stroke survivors (≥80 years) experiencing less favorable outcomes
Poor food access correlates with higher MASLD and frailty prevalence in liver transplant candidates, with geospatial clustering highlighting socioeconomic and environmental determinants impacting transplant candidacy and outcomes.
A 2022 national study shows frailty, not chronological age, is a stronger predictor of 30-day postoperative mortality across surgical risk levels, challenging age-based surgical decision-making.
Declines in frailty, intrinsic capacity, and physical quality of life occur years before cardiovascular events, highlighting a prolonged window for early intervention in older adults.
Frailty negatively impacts swallowing improvement after UES surgery for cricopharyngeus muscle dysfunction, with nonfrail patients experiencing greater benefits. Frailty assessment aids preoperative planning without excluding patients from
Semaglutide demonstrates consistent cardiovascular benefits and safety across frailty levels in overweight adults with cardiovascular disease, enhancing quality of life and frailty status without increased adverse events.
This study identifies baseline frailty, organ dysfunction severity, and corticosteroid use as independent predictors of severe post-intensive care frailty in older septic shock survivors, highlighting critical factors for targeted post-ICU
This study explores how economic, educational, healthcare, neighborhood, and social factors link to multiple frailty dimensions in Chinese older adults, highlighting cognition as a key intermediary.
A metabolomic clock based on plasma metabolites accurately estimated chronological age (r=0.92) and was associated with mortality, frailty, and cognitive impairment across two European cohorts.
In frail elderly Asian AF patients stable on warfarin, transitioning to DOACs increased risks of bleeding, thromboembolic events, and mortality, emphasizing cautious individualized management.
In a binational registry study of 615,719 ICU admissions, ICU readmission was linked to a similar absolute increase in 60-day mortality in frail and nonfrail patients, although frail readmitted patients had the highest overall mortality.
This review synthesizes evidence from the GISSG+2201 trial and related studies, demonstrating that supervised multimodal prehabilitation significantly reduces postoperative complications and enhances functional recovery in older, frail pati
The ESPRIT trial reveals that targeting systolic blood pressure below 120 mmHg significantly reduces cardiovascular events across diverse populations, including frail patients and those with diabetes, while uniquely improving retinal microv
A large-scale Medicare study suggests that SGLT-2 inhibitors and GLP-1 receptor agonists significantly slow frailty progression in older adults with type 2 diabetes, independent of their cardiovascular benefits, marking a potential shift in
A secondary analysis of the TTM2 trial reveals that frailty is a potent predictor of mortality and poor neurological outcomes after out-of-hospital cardiac arrest, with severely frail patients facing a 35-fold higher risk of poor functional
The 2025 AHA scientific statement provides practical, patient-centered guidance for coronary revascularization in older adults, emphasizing geriatric assessment, individualized strategy selection, and shared decision-making.
In a 497,185‑patient registry study, frailty (CFS ≥5) was common and associated with substantially higher in‑hospital mortality across all severities of acute hypoxemic respiratory failure (AHRF). The relationship between PaO2/FiO2 and deat
A pragmatic multicenter randomized trial found that coach-supported, home-based multimodal prehabilitation before elective noncardiac surgery did not reduce 30-day postoperative disability or in-hospital complications in older adults with f
In the RETREAT-FRAIL randomized trial of nursing-home residents ≥80 years with systolic BP <130 mm Hg, a protocolized step-down of antihypertensive drugs reduced medication burden and raised systolic BP modestly but did not change all-ca
The FINEARTS-HF trial demonstrates finerenone’s efficacy and safety in reducing heart failure events, improving symptoms, and lowering new-onset diabetes risk, with consistent benefits across sex, ejection fraction ranges, frailty levels, a
